
    
      The investigators will recruit 20 patients with allergic contact dermatitis who have not
      improved with allergen avoidance up to 6 months after patch testing, but where allergic
      contact dermatitis is still suspected. Subjects will receive 10 weeks of dupilumab, and both
      clinical data and tissue samples will be assessed.
    
  